PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34863997-10 2022 Dex decreased LPS-induced IL-1beta, TNF-alpha, and catecholamine but increased acetylcholine in blood serum; these effects of Dex was partially abolished by vagotomy. Dexmedetomidine 0-3 interleukin 1 alpha Rattus norvegicus 26-34 34863997-10 2022 Dex decreased LPS-induced IL-1beta, TNF-alpha, and catecholamine but increased acetylcholine in blood serum; these effects of Dex was partially abolished by vagotomy. Dexmedetomidine 126-129 interleukin 1 alpha Rattus norvegicus 26-34 35449859-8 2022 Dex-treated rats were also associated with a decrease in TNF-alpha, IL-1beta, and IL-6 expression in alveolar lavage fluid (BALF). Dexmedetomidine 0-3 interleukin 1 alpha Rattus norvegicus 68-76 34622713-7 2021 Compared with SD group, the escape latency was shortened, original platform-crossing times increased, MDA content declined, SOD activity rose, neurons were arranged orderly and number of Nissl bodies increased in the hippocampal CA1 region, levels of IL-1beta, TNF-alpha, and IL-6 in the hippocampus decreased, Rac1/AKT/NF-kappaB expressions were down-regulated, and proportion of NF-kappaB entering the nucleus declined in SD+DEX group (P < 0.05). Dexmedetomidine 427-430 interleukin 1 alpha Rattus norvegicus 251-259 34182937-8 2021 In addition, dexmedetomidine post-conditioning attenuated the serum levels of the pro-inflammatory cytokine tumor necrosis factor (TNF)-alpha at 2 h, as well as interleukin IL-1beta at 2, 24, and 48 h. TUNEL staining showed that the number of apoptotic cells in the dexmedetomidine post-conditioning group was significantly reduced compared with the control group. Dexmedetomidine 13-28 interleukin 1 alpha Rattus norvegicus 173-181 34182937-8 2021 In addition, dexmedetomidine post-conditioning attenuated the serum levels of the pro-inflammatory cytokine tumor necrosis factor (TNF)-alpha at 2 h, as well as interleukin IL-1beta at 2, 24, and 48 h. TUNEL staining showed that the number of apoptotic cells in the dexmedetomidine post-conditioning group was significantly reduced compared with the control group. Dexmedetomidine 266-281 interleukin 1 alpha Rattus norvegicus 173-181 35486975-9 2022 Dex preconditioning reduced the expression of the proinflammatory cytokines IL-1beta, TNF-alpha and IL-6 in hippocampus. Dexmedetomidine 0-3 interleukin 1 alpha Rattus norvegicus 76-84 35488217-8 2022 RESULTS: DEX significantly decreased apoptosis rates and inhibited interleukin 1 beta (IL-1beta), tumor necrosis factor alpha (TNF-alpha), and interleukin 6 (IL-6) release (P < 0.05). Dexmedetomidine 9-12 interleukin 1 alpha Rattus norvegicus 87-95 34848804-8 2021 In alveolar macrophages and endothelial cells, dexmedetomidine decreased IL-6 and IL-1beta compared to STROKE (p = 0.002, and p = 0.040, respectively), and reduced IL-1beta compared to propofol (p = 0.014). Dexmedetomidine 47-62 interleukin 1 alpha Rattus norvegicus 82-90 34848804-8 2021 In alveolar macrophages and endothelial cells, dexmedetomidine decreased IL-6 and IL-1beta compared to STROKE (p = 0.002, and p = 0.040, respectively), and reduced IL-1beta compared to propofol (p = 0.014). Dexmedetomidine 47-62 interleukin 1 alpha Rattus norvegicus 164-172 35392150-9 2022 The use of SGB or Dex alone could significantly reduce the rate of pulmonary edema and lung cell apoptosis in HFD-induced obese rats and reduce MPO, TNF-alpha, IL-1beta, and MCP1 levels, increasing the activity of SOD and GSH-Px. Dexmedetomidine 18-21 interleukin 1 alpha Rattus norvegicus 160-168 33287729-9 2020 RESULTS: Dexmedetomidine pretreatment attenuated neurological injury, brain lesions and expression of inflammatory factors (IL-1beta, IL-6, TNF-alpha) after brain ischemia (P < 0.05). Dexmedetomidine 9-24 interleukin 1 alpha Rattus norvegicus 124-132 33383282-9 2021 RESULTS: DEX preconditioning significantly reduced the intestinal pathological Chiu"s score, serum I-FABP, intestinal TNF-alpha, IL-1beta levels, and the protein expression of TLR4, MyD88, and NF-kappaB in the rats with intestinal I/R injury. Dexmedetomidine 9-12 interleukin 1 alpha Rattus norvegicus 129-137 33499703-12 2021 The expression of CXCL13, CXCR5, caspase-3, IL-6, TNF-alpha, IL-1beta were reduced by DEX postconditioning. Dexmedetomidine 86-89 interleukin 1 alpha Rattus norvegicus 61-69 32707303-13 2020 Therefore, DEX reduces the levels of two mediators that are activated by the NLRP3 inflammasome: IL-18 and IL-1beta. Dexmedetomidine 11-14 interleukin 1 alpha Rattus norvegicus 107-115 32705282-10 2020 It was demonstrated that Dex administration significantly alleviated LPS-induced ALI, downregulated the secretion of IL-1beta, decreased the expression of NLRP3, inhibited the phospho-activation of p38 and increased HO-1 expression. Dexmedetomidine 25-28 interleukin 1 alpha Rattus norvegicus 117-125 32309111-8 2020 In the Dex group, the escape latency was shorter, neuron cell injury levels were alleviated, and the expression levels of TNF-alpha and IL-1beta were significantly down-regulated compared with the POCD group. Dexmedetomidine 7-10 interleukin 1 alpha Rattus norvegicus 136-144 32317860-7 2020 Furthermore, in response to I/R, the DEX treatment reduced the mRNA expression of TNF-alpha, IL-1beta, IL-6, and MCP-1 in the kidney tissues and the serum levels of TNF-alpha, IL-1beta, IL-6, and MCP-1. Dexmedetomidine 37-40 interleukin 1 alpha Rattus norvegicus 93-101 32317860-7 2020 Furthermore, in response to I/R, the DEX treatment reduced the mRNA expression of TNF-alpha, IL-1beta, IL-6, and MCP-1 in the kidney tissues and the serum levels of TNF-alpha, IL-1beta, IL-6, and MCP-1. Dexmedetomidine 37-40 interleukin 1 alpha Rattus norvegicus 176-184 31257507-11 2019 Additionally, on the first day after surgery, the expression levels of IL-1beta, TNF-alpha and NF-kappaB in the hippocampi of rats in the low- and high-dose dexmedetomidine anesthesia groups were significantly lower than those in the model group, and the decrease was more pronounced in the high-dose group. Dexmedetomidine 157-172 interleukin 1 alpha Rattus norvegicus 71-79 32742334-12 2020 Inhibition of miR-17-3p in Dex-induced H9C2 cells during H/R increased the expression of inflammatory mediators including tumor necrosis factor-alpha, interleukin (IL)-6, IL-1beta and phosphorylated NFkappaB subunit p65, while Dex reduced the H/R-induced expression of these inflammatory mediators. Dexmedetomidine 27-30 interleukin 1 alpha Rattus norvegicus 171-179 32415933-11 2020 Compared with those in the model group, rats in the DEX group had significantly lower expression levels of serum BUN, Cre, IL-1beta, and IL-6, and oxidant markers MDA and ROS, but significantly higher expression levels of miR-146a and antioxidant markers SOD and CAT. Dexmedetomidine 52-55 interleukin 1 alpha Rattus norvegicus 123-131 32163856-5 2020 In adjuvant-induced arthritis (AA) rat models, DEX (10 mug/kg and 20 mug/kg) reduced the pathological score, the arthritis score, paw swelling volume, and the serum levels of IL-1beta, IL-6, IL-17A, and TNF-alpha. Dexmedetomidine 47-50 interleukin 1 alpha Rattus norvegicus 175-183 32163856-6 2020 Moreover, by using Western blot and real-time quantitative PCR (RT-qPCR), it was demonstrated that DEX can inhibit the expression of IL-1beta, IL-6, MMP-3, MMP-9 and P-P65 in the synovial tissue of AA rats. Dexmedetomidine 99-102 interleukin 1 alpha Rattus norvegicus 133-141 32016469-7 2020 Pretreatment with dexmedetomidine significantly inhibited the oxidative stress response and proinflammatory factor release caused by IIR compared with the normal saline group (MDA and SOD in lung and plasma, P<0.05; MPO, IL-1beta and TNF-alpha in lung and plasma, P<0.05). Dexmedetomidine 18-33 interleukin 1 alpha Rattus norvegicus 224-232 31478596-10 2019 Furthermore, DEX treatment markedly prevented the downregulation of inflammatory response factors, TNF-alpha, IL-1beta and NF-kappaB, and IL-6. Dexmedetomidine 13-16 interleukin 1 alpha Rattus norvegicus 110-118